0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover626.04%IV-509.76%PremiumSep 20, 2024Expiry Date8.36Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6942Delta0.1494Gamma0.19Leverage Ratio-0.0202Theta-0.0034Rho-0.13Eff Leverage0.0013Vega
Syros Pharmaceuticals Stock Discussion
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen in acute myeloid leukemi...
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
Syros Pharmaceuticals (NASDAQ:SYRS) announced the discontinuation of enrollment in its SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. The trial compared a triplet regimen (tamibarotene, venetoclax, and azacitidine) to a doublet regimen (venetoclax and azacitidine) in newly diagnosed, unfit AML patients with RARA gene overexpression.
The decision was based on a prespe...
Might be seeing an NDA as soon as next year if things keep looking up from the phase 3 results!
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update :: Syros Pharmaceuticals, Inc. (SYRS)
No comment yet